What is Solid Biosciences?
Solid Biosciences operates as a specialized life sciences enterprise dedicated to the research and development of transformative gene therapy candidates. The company's core portfolio includes SGT-003, targeting Duchenne muscular dystrophy, alongside SGT-501 and AVB-401, which address catecholaminergic polymorphic ventricular tachycardia and BAG3-mediated dilated cardiomyopathy, respectively. By integrating deep scientific expertise with a patient-centric philosophy, the firm bridges the gap between molecular discovery and clinical application. Their market position is defined by a commitment to addressing high-unmet-need diseases, effectively positioning them as a critical player in the next generation of precision medicine and rare disease management.
How much funding has Solid Biosciences raised?
Solid Biosciences has raised a total of $455M across 3 funding rounds:
Stock Offering
$125M
Share Placement
$90M
Stock/Share Issuance
$240M
Stock Issuance/Offering (2018): $125M, investors not publicly disclosed
Share Placement (2020): $90M led by EcoR1 Capital, Perceptive Advisors, Ikarian Capital, Bain Capital, Aspire Capital Fund, RA Capital Management, Boxer Capital, and Suvretta Capital Management
Stock/Share Issuance (2026): $240M, investors not publicly disclosed
Key Investors in Solid Biosciences
EcoR1 Capital
A San Francisco-based investment fund specializing in the biotech sector, focused on building long-term partnerships with entrepreneurs to advance therapeutic innovation.
Perceptive Advisors
A New York-based investment firm managing significant assets with a dedicated focus on funding innovative healthcare and life sciences technologies.
Bain Capital
A leading global private investment firm that provides flexible capital solutions and strategic value-add services to companies across various sectors, including healthcare.
What's next for Solid Biosciences?
With the recent capital injection, Solid Biosciences is poised to transition its primary assets through critical clinical milestones. The strategic focus will likely center on scaling manufacturing capabilities and advancing the SGT-003 program toward pivotal data readouts. As the company matures, the emphasis will shift from early-stage research to robust clinical validation, requiring disciplined capital allocation to maintain its competitive edge in the gene therapy sector. Investors will be closely monitoring the firm's ability to translate its scientific pipeline into tangible patient outcomes, which remains the primary driver of long-term enterprise value in the biotech industry.
See full Solid Biosciences company page
